Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The FB-8 study is designed as an open label, single arm, Phase I dose-escalation study
evaluating the combination of weekly paclitaxel with neratinib and trastuzumab in women with
metastatic, HER2-positive breast cancer. The primary aim of this study is to determine the
safety and tolerability of the three-drug combination.